Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Gemcitabine + Nab-paclitaxel + VG161 |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Gemcitabine | Gemzar | Difluorodeoxycytidine Hydrochlorothiazide|LY-188011 | Chemotherapy - Antimetabolite 14 | Gemzar (gemcitabine) is converted in cells to difluorodeoxycytidine di- and triphosphate (dFdCDP, dFdCTP), which act to inhibit ribonucleoside reductase and as a deoxynucleotide analog respectively, resulting in DNA strand termination and apoptosis (NCI Drug Dictionary). |
Nab-paclitaxel | Abraxane | ABI-007|Paclitaxel Protein-bound | Chemotherapy - Taxane 3 | Abraxane (nab-paclitaxel) is an albumin-stablized version of paclitaxel, which binds microtubules and prevents depolymerization, resulting in decreased cell motility and division (NCI Drug Dictionary). |
VG161 | VG-161|VG 161 | VG161 is an oncolytic herpes simplex virus-1 (HSV-1) engineered to express IL-12, IL-15, IL15Ra, and a PD-L1 (CD274)/PD-1 blocking peptide, which may induce antitumor immune response and decrease tumor growth (PMID: 36042555). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|